down arrow

BiomX, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US09090D1037
USD
4.77
0.26 (5.76%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

4.474.81

52 Week

4.1022.06
Valuation
Technical
Day's Volume

CASH

26.93 k

Shareholding (Mar 2025)

FII

0.20%

Held by 4 FIIs

DII

75.08%

Held by 1 DIIs

Promoter

24.69%

How big is BiomX, Inc.?

22-Jun-2025

As of Jun 18, BiomX, Inc. has a market capitalization of 10.21 million, with net sales of 0.00 million and a net profit of -16.15 million over the latest four quarters. Shareholder's funds are at 24.15 million, and total assets amount to 98.81 million.

As of Jun 18, BiomX, Inc. has a market capitalization of 10.21 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -16.15 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 24.15 million and Total Assets at 98.81 million.

Read More

What does BiomX, Inc. do?

22-Jun-2025

BiomX, Inc. is a microbiome company specializing in natural and engineered phage therapies in the Pharmaceuticals & Biotechnology sector. As of March 2025, it has a market cap of $10.21 million and reported a net profit loss of $8 million.

Overview: <BR>BiomX, Inc. is a microbiome company focused on developing natural and engineered phage therapies within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -8 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 10.21 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.81 <BR>Return on Equity: -177.29% <BR>Price to Book: 0.42<BR><BR>Contact Details: <BR>Address: 7 Pinhas Sapir St, Floor 2, NESS-ZIONA NY: 7414002 <BR>Tel: 1 646 4659000

Read More

Who are in the management team of BiomX, Inc.?

22-Jun-2025

As of March 2022, the management team of BiomX, Inc. includes Dr. Russell Greig (Independent Chairman), Mr. Jonathan Solomon (CEO), and several independent directors: Dr. Gbola Amusa, Mr. Jonas Grossman, Dr. Alan Moses, Mr. Paul Sekhri, and Ms. Lynne Sullivan. They are responsible for the company's strategic direction.

As of March 2022, the management team of BiomX, Inc. includes the following individuals:<BR><BR>- Dr. Russell Greig, Independent Chairman of the Board<BR>- Mr. Jonathan Solomon, Chief Executive Officer and Director<BR>- Dr. Gbola Amusa, Independent Director<BR>- Mr. Jonas Grossman, Independent Director<BR>- Dr. Alan Moses, Independent Director<BR>- Mr. Paul Sekhri, Independent Director<BR>- Ms. Lynne Sullivan, Independent Director<BR><BR>This team is responsible for guiding the strategic direction of the company.

Read More

Is BiomX, Inc. technically bullish or bearish?

20-Sep-2025

As of August 27, 2025, BiomX, Inc. is in a mildly bearish trend, with daily moving averages and weekly RSI indicating weakness, despite a mildly bullish MACD, and it has significantly underperformed the S&P 500 with year-to-date and one-year returns of -30.31% and -50.41%, respectively.

As of 27 August 2025, the technical trend for BiomX, Inc. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by the daily moving averages indicating a mildly bearish position and the weekly RSI showing bearish momentum. While the MACD is mildly bullish on both weekly and monthly time frames, the overall indicators suggest weakness. Additionally, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -30.31% versus the S&P 500's 12.22%, and a one-year return of -50.41% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 13 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.72

stock-summary
Return on Equity

-209.13%

stock-summary
Price to Book

0.69

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-51.46%
0%
-51.46%
6 Months
-51.06%
0%
-51.06%
1 Year
-60.26%
0%
-60.26%
2 Years
-90.71%
0%
-90.71%
3 Years
-90.56%
0%
-90.56%
4 Years
-98.59%
0%
-98.59%
5 Years
-99.57%
0%
-99.57%

BiomX, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is BiomX, Inc. technically bullish or bearish?

As of 27 August 2025, the technical trend for BiomX, Inc. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by the daily moving averages indicating a mildly bearish position and the weekly RSI showing bearish momentum. While the MACD is mildly bullish on both weekly and monthly time frames, the overall indicators suggest weakness. Additionally, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -30.31% versus the S&P 500's 12.22%, and a one-year return of -50.41% compared to the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-7.19%
EBIT to Interest (avg)
-16.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.81
Sales to Capital Employed (avg)
0
Tax Ratio
0.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
74.66%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.50
EV to EBIT
0.20
EV to EBITDA
0.21
EV to Capital Employed
-1.67
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-177.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 1 Schemes (0.03%)

Foreign Institutions

Held by 4 Foreign Institutions (0.2%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -700.00% vs 115.62% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.10",
          "val2": "-9.40",
          "chgp": "24.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.50",
          "val2": "11.90",
          "chgp": "-87.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.00",
          "val2": "1.00",
          "chgp": "-700.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 32.44% vs 7.42% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-37.20",
          "val2": "-26.80",
          "chgp": "-38.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.80",
          "val2": "2.50",
          "chgp": "12.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "18.30",
          "val2": "0.10",
          "chgp": "18,200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.70",
          "val2": "-26.20",
          "chgp": "32.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-7.10
-9.40
24.47%
Interest
0.00
0.00
Exceptional Items
1.50
11.90
-87.39%
Consolidate Net Profit
-6.00
1.00
-700.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -700.00% vs 115.62% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-37.20
-26.80
-38.81%
Interest
2.80
2.50
12.00%
Exceptional Items
18.30
0.10
18,200.00%
Consolidate Net Profit
-17.70
-26.20
32.44%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 32.44% vs 7.42% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About BiomX, Inc. stock-summary
stock-summary
BiomX, Inc.
Pharmaceuticals & Biotechnology
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Company Coordinates stock-summary
Company Details
7 Pinhas Sapir St , Floor 2 , NESS-ZIONA NY : 7414002
stock-summary
Tel: 1 646 4659000
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."